Induced pluripotent stem cells, or iPSCs, have reshaped how researchers study human disease. By enabling scientists to generate patient-specific cell models in the lab, iPSCs offer a powerful way to investigate disease biology in systems that are often more relevant than traditional animal or immortalized cell models.
Over the last two decades, iPSC technology has moved from a breakthrough discovery to a foundational tool in disease modeling, drug discovery, and translational research. Because iPSCs can be generated from adult cells and then directed into a wide range of specialized cell types, they give researchers a flexible platform for studying complex diseases in a more human-relevant context.
iPSCs are adult cells that have been reprogrammed into a pluripotent state, allowing them to become many different cell types used in research.
They allow scientists to create patient-specific cell models that reflect the genetic background of disease more closely than many traditional systems.
Researchers use iPSCs to study disease mechanisms, compare healthy and disease-associated cell behavior, support drug discovery, and explore gene-editing strategies. In some areas of research, iPSCs are also being investigated as a potential source for cell-based therapies, including cell replacement approaches.
In this article, we explore what iPSCs are, why they have become so important in biomedical research, and how they are helping bridge the gap between early discovery and future therapeutic development.
iPSCs were first introduced in 2006 through the pioneering work of Shinya Yamanaka and colleagues, who demonstrated that adult somatic cells could be reprogrammed into a pluripotent state using defined transcription factors. This discovery fundamentally changed stem cell biology by showing that differentiated cells could be reset to a state with the capacity to become many functionally relevant cell types.¹˒²
In practical terms, cells collected from a patient, such as skin fibroblasts or blood cells, can be reprogrammed into iPSCs and then differentiated into disease-relevant cell types for study. Researchers can use these cells to model aspects of neurological, cardiac, muscular, hepatic, and other disorders in vitro. This patient-specific approach has made iPSCs especially valuable for studying diseases that are difficult to access directly in living patients.
What makes iPSCs so impactful is not just their pluripotency, but their relevance. Instead of relying solely on proxy systems, researchers can investigate disease in cells that carry the patient’s own genetic background. That opens the door to studying how specific mutations, risk variants, or cellular pathways contribute to disease onset and progression.
One of the defining strengths of iPSC technology is its versatility. Once established, iPSC lines can be differentiated into specialized cells such as neurons, cardiomyocytes, and hepatocyte-like cells, allowing researchers to build models tailored to specific disease areas.³
Just as importantly, iPSCs can reproduce key features of disease biology in vitro. In many cases, they allow researchers to examine pathogenic mechanisms directly in human cells rather than inferring them from nonhuman models.⁴ For complex diseases, this can provide a more precise view of how cellular dysfunction emerges and evolves. In addition, these models are widely used in drug screening and therapeutic discovery, enabling researchers to evaluate compound effects, identify potential treatment strategies, and assess safety in a more human-relevant system.
Rare disease research has been one of the most compelling areas of iPSC application. In amyotrophic lateral sclerosis (ALS), for example, iPSC-derived motor neuron models have been used to study disease-associated phenotypes linked to mutations in genes such as TDP-43 and SOD1. These models have helped researchers investigate pathological protein aggregation, cellular stress, and motor neuron vulnerability in a patient-relevant setting. ⁵˒⁶
iPSCs have also played an important role in Duchenne muscular dystrophy (DMD) research. Patient-derived iPSC models have enabled the study of dystrophin-related dysfunction and supported work exploring gene-editing strategies designed to correct disease-causing mutations. These types of models give researchers an experimentally tractable system for testing therapeutic hypotheses before moving into more advanced development stages.
Together, these examples show why iPSCs are more than a theoretical advance. They have become a practical tool for studying disease biology in ways that are more personalized, mechanistic, and clinically relevant.
As iPSC technology has matured, its value has expanded beyond disease modeling alone. Today, iPSCs are increasingly used in combination with advanced genome engineering tools, including CRISPR-Cas9, to build more refined and informative experimental systems.
One major advantage of this combination is the ability to create precise mutation corrections or introduce defined variants into otherwise matched cell lines. This makes it possible to generate isogenic controls—cell lines that differ only at a specific genetic locus—so researchers can isolate the biological effects of a mutation with greater confidence.⁷˒⁸
Researchers can also derive iPSC lines directly from patients whose cells carry disease-associated mutations. Those lines can then be differentiated into target cell types for downstream characterization, pathway analysis, and therapeutic testing.⁹ This workflow helps preserve the genetic context of disease while enabling more controlled experimentation in vitro.
The implications for translational research are significant. iPSC models have contributed to mechanistic insights in areas such as neurodegeneration, cardiac disease, and inherited disorders by helping researchers connect genotype to cellular phenotype.³˒¹⁰˒¹¹ In some settings, iPSC-derived cells are also being used to evaluate drug responses and safety signals in a more human-relevant framework than some traditional preclinical systems.
This does not mean iPSCs eliminate the need for other model systems. Rather, they add an important layer of biological relevance that can complement existing tools and help researchers make more informed decisions earlier in development. As workflows continue to improve, iPSCs are strengthening their role in preclinical research by providing higher-confidence, human-relevant data within disease-specific genetic contexts—enhancing predictability without replacing the need for clinical validation.
The impact of iPSCs on disease modeling is already substantial, but the field is still evolving. Improvements in reprogramming, differentiation, genome editing, and assay development continue to expand what researchers can do with these models.
For complex diseases in particular, iPSCs offer something especially valuable: the ability to study human biology in a system that is both experimentally accessible and genetically relevant. That combination is helping researchers better understand disease mechanisms, test hypotheses with greater precision, and move closer to more predictive models of therapeutic response.
As the technology continues to mature, iPSCs are likely to play an even greater role in connecting early-stage discovery with translational research. For scientists working to understand difficult diseases, that makes them not just a useful tool, but a transformative one.
iPSCs have changed the landscape of disease modeling by giving researchers access to patient-specific, versatile cell models that can illuminate the biology of complex disorders. From rare disease research to gene editing and translational studies, their influence continues to grow across biomedical science.
Their true value lies in how they help connect questions of mechanism to opportunities for intervention. By enabling more relevant human cell models, iPSCs support a deeper understanding of disease and a more informed path toward therapeutic development.
As research continues to advance, iPSCs will remain central to efforts aimed at making preclinical studies more predictive, more personalized, and more biologically meaningful.
Author:
Dr. Xinyu Kong, PhD
Director of iPSC Generation and Gene Editing
iXCells Biotechnologies
With over a decade of experience in cellular biology and preclinical research, iXCells delivers human-relevant models that help researchers improve predictability and move new therapies forward.
